Ejby, Dänemark (ots/PRNewswire) – Heute hat Scantox zusammen mit seinem Mehrheitseigentümer Impilo die Übernahme von QPS Neuropharmacology abgeschlossen, einem führenden Auftragsforschungsunternehmen mit Spezialisierung auf neurodegenerative, seltene Krankheiten und psychische Störungen. Das Unternehmen, das seit heute als Scantox Neuro Teil der Scantox Group ist, ist bekannt für seine hochwertigen, wissenschaftlich fundierten Dienstleistungen und verfügt über eine […] Scantox vollzieht Übernahme QPS Neuropharmacology – jetzt Scantox Neuro

CAMBRIDGE, Mass., April 01, 2024 (GLOBE NEWSWIRE) — Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that Chief Executive Officer and President, Ram Aiyar, Ph.D., Chief Financial Officer, Vineet Agarwal, and Chief Scientific Officer, Steve Colletti, Ph.D., will participate, present, and meet investors regarding progress of KRRO-110, Korro’s best-in-class candidate for AATD, at the following upcoming investor conferences: Korro to Participate in Upcoming Investor Conferences

COPENHAGEN, Denmark, April 2, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today that JYNNEOS®, the only FDA-approved mpox vaccine, is now commercially available in the U.S., marking a significant expansion for access to JYNNEOS® by establishing additional pathways for vaccine procurement, distribution, and reimbursement by both public and private payers. Bavarian Nordic Announces Commercial Launch of Mpox Vaccine in the U.S.

Kelyniam Global (OTC:KLYG) and Fin-ceramica, Faenza S.p.a., makers of custom cranial implants, announced today that the NEOS Surgery Cranial LOOP™ fixation system has received 510(k) clearance from the FDA for use with Finceramica’s CustomizedBone™ hydroxyapatite cranial implant. The Cranial LOOP™ family of cranial fixation devices is a smart system made of PEEK-OPTIMA™, a biocompatible polymer, for securely fixing bone flaps after craniotomies. With more than 10 years of market experience, Cranial LOOP™ is being used in public and private hospitals in 25 countries worldwide. Cranial LOOP™ was first cleared by the FDA in 2010.  The most recent 510k clearance is for use specifically with Finceramica’s CustomizedBone™ hydroxyapatite cranial implant.

Kelyniam Global (OTC:KLYG) and Fin-ceramica, Faenza S.p.a., makers of custom cranial implants, announced today that the NEOS Surgery Cranial LOOP™ fixation system has received 510(k) clearance from the FDA for use with Finceramica’s CustomizedBone™ hydroxyapatite cranial implant. The Cranial LOOP™ family of cranial fixation devices is a smart system made of PEEK-OPTIMA™, a biocompatible polymer, for securely fixing bone flaps after craniotomies. With more than 10 years of market experience, Cranial LOOP™ is being used in public and private hospitals in 25 countries worldwide. Cranial LOOP™ was first cleared by the FDA in 2010.  The most recent 510k clearance is for use specifically with Finceramica’s CustomizedBone™ hydroxyapatite cranial implant.

Forschenden am US-amerikanischen National Institute of Standards and Technology (NIST) gelang die Messung der Glukosekonzentration mit Hilfe eines Mobiltelefons. Das berichtet die DGKL. Dem Bericht zufolge nutzt die Technik den eingebauten Kompass des Smartphones und die Eigenschaften eines intelligenten Hydrogel-Aktuators aus. Hydrogel-Aktuatoren seien Materialien, die auf externe Reize reagieren, indem sie diese in mechanische Bewegung umwandeln. Alles lesen: https://www.dgkl.de/aktuelles/unsere-news/detail?tx_news_pi1%5Bnews%5D=183&cHash=50b6d5b6a19995321b01d1914ea2db55

A new study (DOI: 10.1038/s41378-024-00665-w) published on 12 March, 2024, in the journal Microsystems & Nanoengineering, unveiled an innovative technology that enables multiplexed fluorescence and scatter detection with unprecedented single-cell resolution, using on-chip fiber optics within droplet microfluidic applications. The innovative technology behind the OptiDrop platform marks a significant departure from traditional single-cell analysis methods. By incorporating advanced optical fiber technology directly into microfluidic chips, OptiDrop enables on-chip detection of light scatter and fluorescence from droplets. This novel approach allows for precise analysis of cellular components at a level of detail previously considered unachievable, bypassing the need for complex and costly traditional microscopy and high-speed imaging techniques. The platform has been rigorously tested, demonstrating its ability to perform differential expression analysis of cell surface biomarkers, such as major histocompatibility complex proteins. This not only showcases OptiDrop’s potential for detecting subtle… 

– Publication describes the first gene delivery vector system based on a human commensal virus, the anellovirus – Ring Therapeutics Publishes a Novel Gene Delivery Platform Based on the Commensal Human Anellovirus

ZUG, Switzerland and BOSTON, April 01, 2024 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced an oral presentation at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting, taking place May 7 – 11, 2024, in Baltimore, MD and virtually. CRISPR Therapeutics to Present at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting

ZUG, Switzerland and BOSTON, April 01, 2024 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced an oral presentation at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting, taking place May 7 – 11, 2024, in Baltimore, MD and virtually. CRISPR Therapeutics to Present at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting